首页> 外文期刊>Spine >Artificial nucleus replacement: clinical experience.
【24h】

Artificial nucleus replacement: clinical experience.

机译:人工核置换:临床经验。

获取原文
获取原文并翻译 | 示例
           

摘要

The prosthetic disc nucleus is designed to help treat patients suffering from degenerative disc disease. The device consists of a hydrogel core that is encased in a polyethylene jacket and is intended to restore disc height while permitting normal range of motion. Clinical trials for the prosthetic disc nucleus were first conducted in 1996, and the device was found to be effective in most of the patients that were implanted. Additional trials in 1997-1998 were less successful, with 38% of patients requiring revision surgery because of device migration. Subsequent changes were made to device shapes and to the surgical protocol to facilitate implantation, thereby eliminating the high device migration rates. Following these modifications, the success rate for the device has improved significantly. Clinical data show excellent results with marked improvements in Oswestry and Prolo scores. Overall, disc height measurements have been well maintained within normal physiologic ranges. The prosthetic disc nucleus device is currently undergoing clinical trials in Canada, and an IDE application to the Food and Drug Administration was expected in the fall, 2001.
机译:人工椎间盘核旨在帮助治疗患有退行性椎间盘疾病的患者。该设备由水凝胶芯组成,该水凝胶芯包裹在聚乙烯护套中,旨在在允许正常运动范围的同时恢复椎间盘的高度。人工椎间盘核的临床试验于1996年首次进行,发现该装置在大多数植入患者中均有效。 1997-1998年的其他试验不太成功,有38%的患者因器械移位而需要翻修手术。随后对器械的形状和手术方案进行了更改,以利于植入,从而消除了器械的高迁移率。经过这些修改,设备的成功率已大大提高。临床数据显示出色的结果,Oswestry和Prolo得分明显提高。总体而言,椎间盘高度的测量已很好地保持在正常生理范围内。人工椎间盘髓核装置目前正在加拿大进行临床试验,并且有望在2001年秋季向食品和药物管理局申请IDE。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号